IFPE (Invisalign First Palatal Expander)

Purpose:

This prospective study is aimed to investigate the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions and to compare them with those of traditional maxillary expansion.

Hypothesis:

The null hypothesis will be:

• 1: There are no differences in the inter-canine, inter-molar width, and molar inclination between IFPE and RME groups.
• 2: There are no differences in the arch width, length, size and shape, palatal surface area and volume, plaque index, and white spot lesion formation between IFPE and RME groups.
• 3: There are no differences in patients' experience of perceived pain intensity and discomfort during the first two weeks of treatment between IFPE and RME groups.

Justification:

The Invisalign First System (IFS) has been used in transverse arch development but with less skeletal effects in growing subjects. A new appliance, Invisalign First palatal expander (IFPE), designed to rapidly expand the maxillary arch with a daily change protocol has been introduced. This prospective clinical trial will compare the efficacy and efficiency between IFPE and conventional rapid maxillary expansion (RME) for maxillary arch expansion in mixed dentition. Patient-reported treatment outcomes in terms of quality of life during the treatment will also be investigated.

Objectives:

The broad, long-term objective of the project is to evaluate the efficacy and efficiency of IFPE and compare the treatment outcomes with those of subjects treated with conventional RME.

The specific aim of this research project is to compare the primary (the inter-molar width, molar inclination, the arch width, length, size and shape, palatal surface area and volume) and secondary (plaque index, and white spot lesion formation, difficulties with speech and eating) outcomes between IFPE and conventional RME for maxillary arch expansion in mixed dentition. With the results of this prospective clinical trial, orthodontists will gain knowledge of the efficacy and efficiency of IFEP compared with traditional RME and make their own decisions with the evidence to be provided by this study.

Research Protocol:

Research Design:

A power calculation based on the previous study by Lione et al.12 indicated a sample of 50 patients in each group to estimate inter-first molar width with a minimum difference of 1mm and a standard deviation (SD) of 3mm, with a power of 80%.

This project will be a multi-centre, prospective clinical trial with two parallel arms. The study protocol will be registered on CliniclTrials.gov. Ethical approval will be obtained from the Institute Research Board of the University of British Columbia before trial commencement and informed consent will be required from each subject before entering the study.

The recruitment will occur at two private orthodontic offices: one is an Invisalign diamond provider's office, and the other is a pediatric dentist and orthodontist group office. All the patients who meet the eligibility criteria will be treated with IFPE in the first office. While patients recruited from the second office under the same inclusion criteria will be treated with conventional Hyrax-type RME. The eligibility criteria will include patients of both sexes from 6 - 12 years of age, in mixed dentition with maxillary first molars completely erupted, and transverse maxillary deficiency. In particular, the presence of unilateral or bilateral crossbite, or intermolar width (as measured where the palatal groove meets the gingival margin of the first molar) of 33 mm or less). Exclusion criteria will include the following: multiple and/or advanced caries, missing teeth due to aplasia, trauma, or deep caries, supernumerary teeth, congenital craniofacial malformations or congenital or acquired systematic disease, and previous orthodontic treatment.

For each group, 50 consecutively recruited patients will be treated with IFPE and RME, respectively. For the IFPE group, patients will be treated with IFPE with no other auxiliaries and no enamel interproximal reduction (IPR) will be planned during treatment. Patients will be instructed to wear the expander 20-22 hours/day with a daily change protocol until the maxillary lingual cusps are in contact with the mandibular buccal cusps, followed by passive retention for 6 months. In the RME group, a two-banded Hyrax-type expander with one-quarter turn (0.25mm) every day will be performed until the maxillary lingual cusps are in contact with the mandibular buccal cusps, followed by a passive retention of 6 months. Orthodontic appointments will be scheduled weekly at first, then moved to monthly.

Digital casts before (T1) and after expansion (T2) will be collected and inter-canine width, inter-molar width, molar inclination, palatal width, surface area, and volume will be measured by using Rhino3D v5.0 software (Robert McNeel and Associates, Seattle, Wash). The buccal surfaces of the maxillary molars will be assessed for non-cavitated carious lesions (white spot lesions) using the International Caries Detection and Assessment System (ICDAS) index. The plaque index was assessed using color-based plaque staining. Questionnaires will be given to the patients to fill out on days 1, 7 and 14 regarding level of pain and discomfort, difficulty with speech and eating, interference with daily activities and functional jaw impairment.

Statistical analysis:

SPSS software (version 27.0, IBM Corp. Armonk, NY) will be used for the statistical analyses. Measurements for 10 randomly selected models will be repeated 1 week apart to assess intra-examiner agreement. Intra-class correlation coefficients and Bland-Altman plots will be used to test the intra-examiner agreement. All measurements will be assessed for normality using the Shapiro-Wilks test. Descriptive statistics in the form of median and interquartile ranges (IQR, Q3-Q1) will be reported when the parameters did not show a normal distribution. Changes between T1 and T2 in each group will be analyzed with paired t-test for normal data and Wilcoxon signed-rank test for non-normal data. Intergroup comparison will be evaluated with t-tests or Mann-Whitney U-tests with Bonferroni correction. The significant level was set as P < 0.05.